Abingworth

Company: Abingworth

Description: Abingworth is recognized as a prominent transatlantic investment firm specializing in the life sciences sector. Established in 1973, Abingworth has played a pivotal role in transforming cutting-edge scientific advancements into innovative medications by providing both capital and expertise to exceptional management teams striving to build world-class companies. Over the years, the firm has invested in more than 180 life science companies, contributing to an impressive track record that includes 46 mergers and acquisitions as well as 70 initial public offerings. The firm’s investment strategy is primarily focused on therapeutic areas and is organized into three main categories: seed and early-stage investments, development stage, and clinical co-development. Abingworth is committed to supporting its portfolio companies by leveraging the extensive experience of its team of professionals, who operate from offices located in London, Menlo Park, California, and Boston. On August 1, 2022, Abingworth became part of the Carlyle Group, further enhancing its capacity to assist in the growth and development of its investments in the dynamic life sciences field. Through its strategic approach and deep industry knowledge, Abingworth continues to be a key player in fostering innovation and creating impactful solutions in healthcare.

Industry: Venture Capital and Private Equity

LinkedIn: https://www.linkedin.com/company/abingworth

Domain: http://www.abingworth.com/

Founded: 1973

Location: London, UK

Address: 38 Jermyn Street, London, UK, SW1Y 6DN, GB

Size: 11-50 employees